Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00470483 |
To compare by neuroimaging techniques the way Social Anxiety patients respond to public speaking before and after a drug administration
Condition | Intervention | Phase |
---|---|---|
Social Anxiety Disorder |
Drug: Paroxetine treatment during 8 weeks Drug: Placebo treatment during 8 weeks |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, fMRI and PET Study Comparing Emotional Challenge-Induced Regional Cerebral Blood Flow Changes Before and After 8 Weeks of Treatment With Placebo and Paroxetine in Subjects With Social Anxiety Disorder |
Enrollment: | 56 |
Study Start Date: | January 2007 |
Study Completion Date: | January 2009 |
Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
arm 2: Placebo Comparator |
Drug: Placebo treatment during 8 weeks
comparator
|
arm 1: Active Comparator |
Drug: Paroxetine treatment during 8 weeks
treatment drug
|
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion criteria:
Exclusion criteria:
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | TMT106386 |
Study First Received: | May 3, 2007 |
Last Updated: | March 20, 2009 |
ClinicalTrials.gov Identifier: | NCT00470483 History of Changes |
Health Authority: | Spain: Spanish Agency of Medicines |
Social Anxiety Disorder PET fRMI |
Neurotransmitter Agents Anxiety Disorders Mental Disorders Psychotropic Drugs Antidepressive Agents, Second-Generation |
Phobic Disorders Serotonin Uptake Inhibitors Paroxetine Antidepressive Agents Serotonin |
Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Disease Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Phobic Disorders Paroxetine Serotonin Uptake Inhibitors |
Pharmacologic Actions Pathologic Processes Serotonin Agents Anxiety Disorders Mental Disorders Therapeutic Uses Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |